

## Insurance Tracker

Premium and YoY growth (%)

Aug-24

245

56

139

32

17

21

20

14

YoY

4%

-5%

4%

25%

3%

10%

-13%

15%

**GWP, INRb** 

**Grand Total** 

**Total Public** 

**Total Private** 

Bajaj Allianz

New India

Star Health

ICICI - Lombard

SAHI

## Growth moderates owing to the fire and crop segments

SAHIs outperform industry growth; private players remain flat YoY

- The industry's Gross Written Premium (GWP) increased 4% YoY to INR245b in Aug'24. This was led by the Health and Motor segments, which grew 9.8%/5.9% YoY. The Fire/Crop segments declined 7.3%/3% YoY, while the Marine segment inched up 10.8% YoY. The Overseas Health segment grew 11.5% YoY.
- During the month, the premium for private players grew 4% YoY to INR139.3b vs. a decline of 5% YoY to INR56.5b for public players (mainly due to a 13% YoY decline for New India Assurance). SAHIs outperformed industry growth and reported a GWP of INR32.3b (up ~25% YoY) in Aug′24 (vs. industry growth of 4% YoY), driven by 15% YoY growth in Star Health.
- Among the key players, ICICIGI/Bajaj Allianz reported 10%/3% YoY growth, respectively. STARHEAL/Go Digit posted a 15%/3% YoY GWP growth, while New India reported a decline of 13% YoY in GWP. Tata AIG reported a strong growth of 25% YoY.

## Health business driven by growth in the retail segment

The Overall Health business grew 10% YoY to INR80.4b, of which the Retail Health segment grew 17% YoY to INR39.6b, while the Group Health segment grew 4.8% YoY to INR39.4b. The Overseas Health segment rose 11.5% YoY. Within the Overall Health segment, SAHIs/private multi-line players grew 24%/16% YoY vs. the industry growth of 10%. The Public segment declined 13% YoY, mainly on account of a 23% decline in New India. Within SAHIs, STARHEAL grew 15% YoY on an overall basis, with 14%/41% YoY growth in the Retail Health and Group Health segments, while CARE reported a strong growth of 38%/23% YoY. Within the Retail Health and Group Health segments, Aditya Birla Health surged 43% and 38% YoY, respectively. ILOM posted 43% and 2% YoY growth in Retail Health and Group Health, respectively. Bajaj Allianz clocked a strong growth of 21% YoY in the Retail Health segment and 38% YoY growth in Retail Health segment. The PSU multi-line players posted 4% YoY growth in Retail Health, but a decline of 17% YoY in Group Health. Tata AIG grew 54%/25% in the Retail Health and Group Health segment, respectively.

# Source: GIC, MOFSL

### **Motor segment growing 6% YoY**

The Motor business grew 6% YoY to INR77.9b, led by a 6% YoY growth each in the Motor TP segment (INR45.1b) and Motor OD segment (INR32.8b) in Aug'24. Overall, private multi-line players grew in line with the industry growth of 6% YoY, while public players grew at 5%. ILOM grew 22%/13% YoY in the Motor OD/ Motor TP segments. Bajaj Allianz grew 10% in the OD segment but declined 6% in the Motor TP segment. Acko General posted a strong growth of 24% YoY on an overall basis with 25%/24% YoY growth in the Motor OD/Motor TP segments. TATA AIG clocked 21%/28% YoY growth in the Motor OD/Motor TP segments. Go Digit grew 11% YoY in the OD segment but declined 4% in the Motor TP segment. HDFC Ergo declined 8% /54% YoY in the Motor OD/Motor TP segment.

## YTD performance of key players

SAHIs/private multi-line players gained ~135bp/~5bp market share in Aug'24, while public players lost ~130bp share.

- **ILOM** reported a growth of 17% YoY (market share of 10% vs. 9.4%).
- Bajaj Allianz reported a decline of 4% YoY (market share of 7% vs. 8.1%).
- New India posted a growth of 2% YoY (market share of 13% vs. 14%).
- STARHEAL registered a growth of 17% YoY (market share of 5% vs. 4.8%).
- GO DIGIT recorded a growth of 13% YoY (Flat YoY).

Research Analyst - Prayesh Jain (Prayesh.Jain@MotilalOswal.com)

Research Analyst - Nitin Aggarwal (Nitin.Aggarwal@MotilalOswal.com) | Muskan Chopra (Muskan.Chopra@MotilalOswal.com)





**Exhibit 1: Overall GWP performance of general insurance players** 

INIDA				GWP		Market share				
INRb	Aug-24	Aug-23	YoY	YTDFY25	YTDFY24	YoY	YTDFY25	YTDFY24	YoY bps	
Acko General	1.8	1.5	22%	8.6	7.2	20%	0.7%	0.6%	6	
Bajaj Allianz	17.4	16.8	3%	88.7	92.3	-4%	7.0%	8.1%	-103	
Cholamandalam MS	7.2	6.7	8%	33.3	29.8	12%	2.6%	2.6%	4	
Zuno	0.9	0.7	28%	3.9	2.7	45%	0.3%	0.2%	8	
Future Generali	3.7	3.4	10%	24.1	19.2	25%	1.9%	1.7%	23	
Go Digit	6.5	6.3	3%	36.8	32.7	13%	2.9%	2.9%	7	
HDFC ERGO	17.5	22.6	-23%	71.5	68.9	4%	5.7%	6.0%	-35	
Navi General *	0.0	0.1	-31%	0.2	0.3	-20%	0.0%	0.0%	-1	
ICICI -Lombard	21.4	19.4	10%	125.9	107.2	17%	10.0%	9.4%	62	
IFFCO - Tokio	7.4	7.0	7%	33.4	40.3	-17%	2.7%	3.5%	-87	
Kotak Mahindra	1.6	1.2	36%	7.7	5.5	40%	0.6%	0.5%	13	
Liberty General	1.9	1.8	9%	9.5	9.3	2%	0.8%	0.8%	-6	
Magma HDI	2.0	1.9	6%	13.0	10.3	27%	1.0%	0.9%	13	
Raheja QBE	0.4	0.1	204%	2.0	0.7	213%	0.2%	0.1%	11	
Reliance General	10.1	9.3	9%	53.2	46.7	14%	4.2%	4.1%	13	
Royal Sundaram	3.1	3.0	4%	16.3	14.1	16%	1.3%	1.2%	6	
SBI General	13.5	12.5	8%	52.0	43.1	20%	4.1%	3.8%	35	
Shriram General	2.8	2.5	13%	12.9	10.4	24%	1.0%	0.9%	11	
Tata-AIG	13.8	11.1	25%	71.9	62.5	15%	5.7%	5.5%	24	
Universal Sompo	6.3	6.1	3%	21.3	19.3	10%	1.7%	1.7%	0	
Private Players	139.3	133.7	4%	686.3	622.4	10%	54.5%	54.4%	4	
United India	13.9	13.0	8%	87.5	79.4	10%	6.9%	6.9%	0	
National	11.5	13.4	-14%	62.9	60.4	4%	5.0%	5.3%	-29	
New India	20.2	23.1	-13%	162.5	159.4	2%	12.9%	13.9%	-105	
Oriental	10.8	9.7	12%	79.6	71.8	11%	6.3%	6.3%	4	
Public Players	56.5	59.2	-5%	392.5	371.0	6%	31.2%	32.5%	-130	
Aditya Birla	3.0	2.1	42%	17.1	12.4	37%	1.4%	1.1%	27	
ManipalCigna	1.4	1.2	13%	6.9	6.2	11.3%	0.5%	0.5%	1	
Care Insurance	7.9	6.1	30%	34.5	26.4	30.8%	2.7%	2.3%	43	
Star Health	14.0	12.2	15%	63.4	54.4	16.7%	5.0%	4.8%	28	
SAHI	32.3	25.9	25%	148.3	119.1	24.5%	11.8%	10.4%	135	
AIC (Crop)	16.2	16.1	1%	27.7	26.5	4.7%	2.2%	2.3%	-11	
ECGC (Export & Credit)	0.5	0.6	-14%	4.8	4.2	16.1%	0.4%	0.4%	2	
Specialized PSU	16.7	16.7	0%	32.6	30.6	6.3%	2.6%	2.7%	-10	
Industry	245	236	4%	1,260	1,143	10%	100.0%	100.0%	0	





Exhibit 2: Industry – segmental performance and product mix

INRb			Product Mix						
INND	Aug-24	Aug-23	YoY	YTDFY25	YTDFY24	YoY	YTDFY25	YTDFY24	YoY bps
Fire	13.3	14.3	-7.3%	131.3	128.7	2.1%	10.4%	11.3%	-86
Marine Total	3.8	3.4	10.8%	25.6	22.9	12.0%	2.0%	2.0%	3
Motor Total	77.9	73.5	5.9%	368.9	334.4	10.3%	29.2%	29.3%	-6
Motor OD	32.8	30.9	6.0%	154.7	138.0	12.1%	12.2%	12.1%	17
Motor TP	45.1	42.6	5.9%	214.2	196.5	9.0%	17.0%	17.2%	-23
Health Total	80.4	73.2	9.8%	495.2	443.7	11.6%	39.2%	38.8%	38
Health Retail	39.6	33.9	16.9%	181.6	153.5	18.3%	14.4%	13.4%	95
Health Group	39.4	37.6	4.8%	271.5	232.6	16.7%	21.5%	20.4%	114
Govt Schemes	0.0	0.5	-100.6%	35.3	51.7	-31.6%	2.8%	4.5%	-172
Overseas	1.4	1.2	11.5%	6.7	5.9	13.4%	0.5%	0.5%	1
Crop	48.5	50.0	-3.0%	104.2	94.7	10.0%	8.2%	8.3%	-4
Others	21.7	21.0	3.0%	138.2	118.7	16.4%	10.9%	10.4%	55
Total	245.5	235.5	4.3%	1,263.4	1,143.2	10.5%	100.0%	100.0%	0

Exhibit 3: Growth in Motor OD premium and market share

IND			ľ	Market share					
INR m	Aug-24	Aug-23	YoY	YTDFY25	YTDFY24	YoY	YTDFY25	YTDFY24	YoY bps
Acko General	306	246	25%	1,340	1,019	31%	0.9%	0.7%	13
Bajaj Allianz	2,564	2,337	10%	12,816	10,840	18%	8.3%	7.9%	43
Cholamandalam MS	1,778	1,608	11%	8,327	7,936	5%	5.4%	5.8%	-37
Zuno	233	164	42%	1049.1	667	57%	0.7%	0.5%	19
Future Generali	703	682	3%	3,416	3,572	-4%	2.2%	2.6%	-38
Go Digit	1,892	1,706	11%	8,943	7,234	24%	5.8%	5.2%	54
HDFC ERGO	1,868	2,022	-8%	9,665	7,796	24%	6.2%	5.7%	60
Navi General *	-	1	-100%	0.3	4	-91%	0.0%	0.0%	0
ICICI - Lombard	4,437	3,627	22%	20,925	16,187	29%	13.5%	11.7%	179
IFFCO -Tokio	1,452	2,029	-28%	7,064	9,572	-26%	4.6%	6.9%	-237
Kotak Mahindra	455	312	46%	2,061	1,358	52%	1.3%	1.0%	35
Liberty General	873	845	3%	4,151	3,627	14%	2.7%	2.6%	5
Magma HDI	331	417	-21%	2,237	1,766	27%	1.4%	1.3%	17
Raheja QBE	110	26	320%	472.2	75	531%	0.3%	0.1%	25
Reliance General	1,634	1,324	23%	7,462	5,932	26%	4.8%	4.3%	52
Royal Sundaram	744	932	-20%	3,247	4,175	-22%	2.1%	3.0%	-93
SBI General	1,500	1,215	23%	7,257	4,342	67%	4.7%	3.1%	154
Shriram General	588	503	17%	2,701	2,079	30%	1.7%	1.5%	24
Tata-AIG	3,401	2,811	21%	14,731	12,852	15%	9.5%	9.3%	21
Universal Sompo	778	965	-19%	3,956	3,838	3%	2.6%	2.8%	-22
Private Players	25,645	23,771	8%	1,21,817	1,04,871	16%	78.8%	76.0%	274
United India	1,728	1,626	6%	8,357	7,142	17%	5.4%	5.2%	23
National	1,423	1,334	7%	5,931	7,008	-15%	3.8%	5.1%	-125
New India	2,991	3,163	-5%	13,756	14,562	-6%	8.9%	10.6%	-166
Oriental	965	1,006	-4%	4,821	4,382	10%	3.1%	3.2%	-6
Public Players	7,107	7,130	0%	32,865	33,094	-1%	21.2%	24.0%	-274
Industry	32,752	30,901	6%	1,54,682	1,37,964	12%	100.0%	100.0%	0

Source: General Council of India, MOFSL





Exhibit 4: Growth in Motor TP premium and market share

			М	Market share					
INR m	Aug-24	Aug-23	YoY	YTDFY25	YTDFY24	YoY	YTDFY25	YTDFY24	YoY bps
Acko General	504	405	24%	2,277	1,753	30%	1.1%	0.9%	17
Bajaj Allianz	2,387	2,533	-6%	11,501	12,101	-5%	5.4%	6.2%	-79
Cholamandalam MS	2,571	2,290	12%	11,544	10,812	7%	5.4%	5.5%	-11
Zuno	213	141	50%	927.2	521	78%	0.4%	0.3%	17
Future Generali	871	720	21%	4,381	4,379	0%	2.0%	2.2%	-18
Go Digit	2,929	3,047	-4%	13,674	13,894	-2%	6.4%	7.1%	-69
HDFC ERGO	975	2,104	-54%	5,086	8,787	-42%	2.4%	4.5%	-210
Navi General *	4	8	-55%	11.3	24	-52%	0.0%	0.0%	-1
ICICI - Lombard	4,090	3,615	13%	19,823	16,663	19%	9.3%	8.5%	77
IFFCO -Tokio	1,681	1,959	-14%	7,777	8,909	-13%	3.6%	4.5%	-90
Kotak Mahindra	324	214	52%	1,545	1,042	48%	0.7%	0.5%	19
Liberty General	644	530	22%	2,890	2,451	18%	1.3%	1.2%	10
Magma HDI	1,107	993	12%	5,419	4,510	20%	2.5%	2.3%	23
Raheja QBE	245	64	284%	1002.9	210	377%	0.5%	0.1%	36
Reliance General	1,852	1,825	1%	9,235	8,634	7%	4.3%	4.4%	-8
Royal Sundaram	1,420	1,228	16%	6,917	5,190	33%	3.2%	2.6%	59
SBI General	1,939	1,119	73%	8,839	4,284	106%	4.1%	2.2%	195
Shriram General	1,994	1,760	13%	9,014	7,284	24%	4.2%	3.7%	50
Tata-AIG	3,909	3,052	28%	18,364	16,680	10%	8.6%	8.5%	8
Universal Sompo	888	1,394	-36%	5,537	5,103	9%	2.6%	2.6%	-1
Private Players	30,546	29,002	5%	1,45,764	1,33,231	9%	68.1%	67.8%	25
United India	4,418	3,792	17%	20,748	17,196	21%	9.7%	8.8%	94
National	2,809	2,792	1%	12,654	13,681	-8%	5.9%	7.0%	-106
New India	5,218	4,805	9%	24,365	22,324	9%	11.4%	11.4%	1
Oriental	2,156	2,238	-4%	10,664	10,054	6%	5.0%	5.1%	-14
Public Players	14,601	13,626	7%	68,431	63,255	8%	31.9%	32.2%	-25
Industry	45,147	42,628	6%	2,14,195	1,96,485	9%	100.0%	100.0%	0





Exhibit 5: Growth in Motor premium and market share

INR m		<b>Motor Total</b>		Market share			
IIVK III	Aug-24	Aug-23	YoY	YTDFY25	YTDFY24	YoY bps	
Acko General	810	651	24%	1.0%	0.8%	15	
Bajaj Allianz	4,951	4,870	2%	6.6%	6.9%	-27	
Cholamandalam MS	4,349	3,898	12%	5.4%	5.6%	-22	
Zuno	445	305	46%	0.5%	0.4%	18	
Future Generali	1,573	1,402	12%	2.1%	2.4%	-26	
Go Digit	4,821	4,753	1%	6.1%	6.3%	-19	
HDFC ERGO	2,843	4,126	-31%	4.0%	5.0%	-96	
Navi General *	4	9	-57%	0.0%	0.0%	0	
ICICI -Lombard	8,527	7,242	18%	11.0%	9.8%	122	
IFFCO - Tokio	3,133	3,988	-21%	4.0%	5.5%	-150	
Kotak Mahindra	779	525	48%	1.0%	0.7%	26	
Liberty General	1,517	1,375	10%	1.9%	1.8%	9	
Magma HDI	1,438	1,410	2%	2.1%	1.9%	20	
Raheja QBE	354	90	295%	0.4%	0.1%	31	
Reliance General	3,485	3,150	11%	4.5%	4.4%	17	
Royal Sundaram	2,164	2,161	0%	2.8%	2.8%	-5	
SBI General	3,439	2,334	47%	4.4%	2.6%	178	
Shriram General	2,582	2,263	14%	3.2%	2.8%	38	
Tata-AIG	7,310	5,863	25%	9.0%	8.8%	14	
Universal Sompo	1,667	2,359	-29%	2.6%	2.7%	-10	
Private Players	56,191	52,774	6%	72.5%	71.2%	135	
United India	6,147	5,418	13%	7.9%	7.3%	61	
National	4,232	4,126	3%	5.0%	6.2%	-115	
New India	8,208	7,968	3%	10.3%	11.0%	-69	
Oriental	3,121	3,244	-4%	4.2%	4.3%	-12	
Public Players	21,708	20,756	5%	27.5%	28.8%	-135	
Industry	77,898	73,529	6%	100.0%	100.0%	0	





Exhibit 6: Growth in Health premium and market share

IND			Overa	all Health			Market share			
INR m	Aug-24	Aug-23	YoY	YTDFY25	YTDFY24	YoY	YTDFY25	YTDFY24	YoY bps	
Acko General	872	720	21%	4,328	3,755	15%	0.9%	0.8%	3	
Bajaj Allianz	3,295	2,539	30%	30,890	38,692	-20%	6.2%	8.7%	-248	
Cholamandalam MS	796	747	7%	4,530	3,206	41%	0.9%	0.7%	19	
Zuno	406	357	14%	1549.9	1,114	39%	0.3%	0.3%	6	
Future Generali	1,193	1,188	0%	9,789	5,119	91%	2.0%	1.2%	82	
Go Digit	917	732	25%	5,793	5,764	0%	1.2%	1.3%	-13	
HDFC ERGO	5,059	4,204	20%	25,364	21,179	20%	5.1%	4.8%	35	
Navi General*	45	60	-26%	209.8	251	-17%	0.0%	0.1%	-1	
ICICI -Lombard	5,472	5,048	8%	35,280	28,523	24%	7.1%	6.4%	70	
IFFCO -Tokio	855	960	-11%	3,913	7,932	-51%	0.8%	1.8%	-100	
Kotak Mahindra	657	519	27%	3,038	2,270	34%	0.6%	0.5%	10	
Liberty General	202	195	4%	1,322	1,692	-22%	0.3%	0.4%	-11	
Magma HDI	389	376	3%	3,001	2,082	44%	0.6%	0.5%	14	
Raheja QBE	31	11	183%	209.6	55	282%	0.0%	0.0%	3	
Reliance General	1,134	1,201	-6%	9,512	8,921	7%	1.9%	2.0%	-9	
Royal Sundaram	618	477	29%	3,453	2,223	55%	0.7%	0.5%	20	
SBI General	2,283	2,136	7%	9,909	9,767	1%	2.0%	2.2%	-20	
Shriram General	2	2	10%	13	12	5%	0.0%	0.0%	0	
Tata-AIG	3,442	2,494	38%	14,585	12,016	21%	2.9%	2.7%	24	
Universal Sompo	622	358	74%	3,023	2,445	24%	0.6%	0.6%	6	
Private Players	28,290	24,323	16%	1,69,710	1,57,017	8%	34.3%	35.4%	-111	
United India	4,005	4,300	-7%	37,306	32,930	13%	7.5%	7.4%	11	
National	4,866	5,853	-17%	26,457	24,534	8%	5.3%	5.5%	-19	
New India	7,057	9,217	-23%	82,892	80,800	3%	16.7%	18.2%	-147	
Oriental	4,627	4,140	12%	33,740	32,178	5%	6.8%	7.3%	-44	
Public Players	20,555	23,509	-13%	1,80,394	1,70,442	6%	36.4%	38.4%	-198	
Aditya Birla	2,830	2,007	41%	16,089	11,689	38%	3.2%	2.6%	61	
ManipalCigna	1,356	1,217	11%	6,733	6,041	11%	1.4%	1.4%	0	
Care Insurance	7,722	5,921	30%	33,692	25,436	32%	6.8%	5.7%	107	
Star Health	13,849	11,992	15%	62,708	53,647	17%	12.7%	12.1%	57	
SAHI	31,541	25,371	24%	1,45,102	1,16,285	25%	29.3%	26.2%	310	
Industry	80,386	73,202	10%	4,95,206	4,43,744	12%	100.0%	100.0%	0	





Exhibit 7: Growth in Retail Health premium and market share

			Retai	l Health			N	/larket share	
INR m	Aug- 24	Aug-23	YoY	YTDFY25	YTDFY24	YoY	YTDFY25	YTDFY24	YoY bps
Acko General	84	27	214%	362	117	208%	0.2%	0.1%	12
Bajaj Allianz	989	819	21%	4,257	3,697	15%	2.3%	2.4%	-6
Cholamandalam MS	479	517	-7%	2,434	2,349	4%	1.3%	1.5%	-19
Zuno	7	7	-10%	32.3	47	-31%	0.0%	0.0%	-1
Future Generali	163	163	0%	772	776	-1%	0.4%	0.5%	-8
Go Digit	56	55	2%	255	234	9%	0.1%	0.2%	-1
HDFC ERGO	3,396	2,993	13%	16,172	13,779	17%	8.9%	9.0%	-7
Navi General*	45	40	13%	210.3	194	9%	0.1%	0.1%	-1
ICICI - Lombard	1,413	990	43%	5,748	4,613	25%	3.2%	3.0%	16
IFFCO -Tokio	300	236	27%	1,129	939	20%	0.6%	0.6%	1
Kotak Mahindra	91	91	0%	401	387	3%	0.2%	0.3%	-3
Liberty General	51	62	-19%	254	267	-5%	0.1%	0.2%	-3
Magma HDI	56	44	26%	209	173	21%	0.1%	0.1%	0
Raheja QBE	2	4	-36%	11.4	13	-14%	0.0%	0.0%	0
Reliance General	376	353	7%	1,710	1,520	12%	0.9%	1.0%	-5
Royal Sundaram	172	177	-3%	801	847	-5%	0.4%	0.6%	-11
SBI General	356	525	-32%	1,758	2,309	-24%	1.0%	1.5%	-54
Shriram General	2	2	10%	12	12	3%	0.0%	0.0%	0
Tata-AIG	1,066	694	54%	4,381	3,112	41%	2.4%	2.0%	38
Universal Sompo	94	88	7%	402	413	-3%	0.2%	0.3%	-5
Private Players	9,195	7,885	17%	41,308	35,799	15%	22.7%	23.3%	-57
United India	1,295	1,170	11%	7,004	6,161	14%	3.9%	4.0%	-16
National	1,996	1,944	3%	9,540	8,967	6%	5.3%	5.8%	-59
New India	2,734	2,598	5%	13,187	11,576	14%	7.3%	7.5%	-28
Oriental	1,487	1,515	-2%	7,287	7,268	0%	4.0%	4.7%	-72
Public Players	7,512	7,227	4%	37,018	33,972	9%	20.4%	22.1%	-175
Aditya Birla	1,224	853	43%	5,709	3,790	51%	3.1%	2.5%	68
ManipalCigna	690	587	18%	3,176	2,681	18%	1.7%	1.7%	0
Care Insurance	4,372	3,166	38%	19,453	13,879	40%	10.7%	9.0%	167
Star Health	12,742	11,208	14%	57,081	49,921	14%	31.4%	32.5%	-109
SAHI	22,883	18,752	22%	1,03,280	83,741	23%	56.9%	54.5%	232
Industry	39,589	33,864	17%	1,81,606	1,53,512	18%	100.0%	100.0%	0





Exhibit 8: Growth in Group Health premium and market share

			Group	Health			М	arket share	
INR m	Aug-24	Aug-23	YoY	YTDFY25	YTDFY24	YoY	YTDFY25	YTDFY24	YoY bps
Acko General	762.2	663	15%	3,822	3,433	11%	1.4%	1.5%	-7
Bajaj Allianz	2,124	1,539	38%	16,724	11,007	52%	6.2%	4.7%	143
Cholamandalam MS	316	228	38%	2,090	848	146%	0.8%	0.4%	41
Zuno	391.2	282	39%	1489.7	890	67%	0.5%	0.4%	17
Future Generali	1024.5	1,019	1%	8,559	4,310	99%	3.2%	1.9%	130
Go Digit	857	670	28%	5,509	5,490	0%	2.0%	2.4%	-33
HDFC ERGO	1,636	1,184	38%	9,044	7,258	25%	3.3%	3.1%	21
Navi General*	-0.1	21	-100%	-0.5	58	-101%	0.0%	0.0%	-2
ICICI - Lombard	3,814	3,750	2%	28,334	22,721	25%	10.4%	9.8%	67
IFFCO -Tokio	553	722	-23%	2,765	5,064	-45%	1.0%	2.2%	-116
Kotak Mahindra	565.6	429	32%	2,637	1,883	40%	1.0%	0.8%	16
Liberty General	138.4	114	22%	999	1,298	-23%	0.4%	0.6%	-19
Magma HDI	333	332	0%	2,791	1,909	46%	1.0%	0.8%	21
Raheja QBE	29.1	8	288%	198.2	42	375%	0.1%	0.0%	6
Reliance General	655	773	-15%	7,253	6,939	5%	2.7%	3.0%	-31
Royal Sundaram	444	297	49%	2,633	1,361	94%	1.0%	0.6%	38
SBI General	1,926	1,611	20%	8,145	7,454	9%	3.0%	3.2%	-20
Shriram General	0	0	0%	0	0	0%	0.0%	0.0%	0
Tata-AIG	1,807	1,443	25%	7,969	7,332	9%	2.9%	3.2%	-22
Universal Sompo	511.2	271	89%	2,534	2,032	25%	0.9%	0.9%	6
Private Players	17,887	15,353	17%	1,13,496	91,325	24%	41.8%	39.3%	254
United India	2,755	2,806	-2%	20,046	18,767	7%	7.4%	8.1%	-68
National	2,869	3,784	-24%	15,666	14,562	8%	5.8%	6.3%	-49
New India	4,318	6,612	-35%	56,556	55,192	2%	20.8%	23.7%	-290
Oriental	3,092	2,572	20%	24,980	21,143	18%	9.2%	9.1%	11
Public Players	13,033	15,774	-17%	1,17,248	1,09,663	7%	43.2%	47.1%	-396
Aditya Birla	1,563	1,129	38%	10,134	7,743	31%	3.7%	3.3%	40
ManipalCigna	665	629	6%	3,548	3,351	6%	1.3%	1.4%	-13
Care Insurance	3,251	2,653	23%	13,622	10,923	25%	5.0%	4.7%	32
Star Health	1,098	779	41%	5,578	3,697	51%	2.1%	1.6%	46
SAHI	8,491	6,475	31%	40,802	31,657	29%	15.0%	13.6%	142
Industry	39,411	37,601	5%	2,71,545	2,32,645	17%	100.0%	100.0%	0

Investment in securities market are subject to market risks. Read all the related documents carefully before investing





Explanation of Investment Rating							
Investment Rating	Expected return (over 12-month)						
BUY	>=15%						
SELL	<-10%						
NEUTRAL	< - 10 % to 15%						
UNDER REVIEW	Rating may undergo a change						
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation						

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### **Disclosures**

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motial Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on <a href="https://www.motilaloswal.com">www.motilaloswal.com</a>. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <a href="http://onlinereports.motilaloswal.com/Dormant/documents/List%200f%20Associate%20companies.pdf">http://onlinereports.motilaloswal.com/Dormant/documents/List%200f%20Associate%20companies.pdf</a>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the fsecurities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <a href="https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx">https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx</a>

A graph of daily closing prices of securities is available at <a href="www.nseindia.com">www.nseindia.com</a>, <a href="www.nseindia.com">www.nseindia.com</a>, <a href="www.nseindia.com">www.nseindia.com</a>, <a href="www.nseindia.com</a>, <a href=

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S. MOFSL has entered into a chaperoning

interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer. MOSIPL and therefore may not be subject to NASD rule 27/11 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading

broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

### **Specific Disclosures**

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

#### The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months





- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### **Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263;

www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No::022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.